Research Perspective Volume 11, Issue 16 pp 6591—6601

In silico clinical trials for anti-aging therapies

Figure 2. Biomathematical approaches to accelerate the performance and personalize the use of aging-targeted strategies. The benefit/risk ratio of aging-targeted interventions largely depends on intra- and inter-individual variations of susceptibility to the healthspan-, resilience-, and/or lifespan-promoting effects of the interventions. Stochastic biomathematical modeling and computational simulation platforms should be developed as in silico strategies to accelerate the performance of clinical trials targeting human aging, and to provide personalized approaches and robust biomarkers of healthy aging at the individual-to-population levels.